Mimedx (MDXG) Cost of Revenue (2011 - 2026)

Mimedx has disclosed Cost of Revenue across 16 years of filings, most recently posting $20.0 million for Q2 2026.

• In Q2 2026, Cost of Revenue rose 6.96% year-over-year to $20.0 million; the TTM figure through Jun 2026 stood at $75.1 million (up 11.34% YoY), while the FY2025 annual figure was $73.0 million, up 21.54% from the prior year.
• Cost of Revenue came in at $20.0 million for Q2 2026 at Mimedx, up from $17.4 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $20.0 million in Q2 2026 to a low of $9.9 million in Q1 2022.
• Average Cost of Revenue over 5 years is $15.2 million, with a median of $14.8 million recorded in 2023.
• The largest YoY upside for Cost of Revenue was 102.44% in 2022 against a maximum downside of 7.34% in 2022.
• Over 5 years, Cost of Revenue stood at $14.4 million in 2022, then decreased by 3.67% to $13.8 million in 2023, then rose by 22.16% to $16.9 million in 2024, then climbed by 12.69% to $19.1 million in 2025, then increased by 4.86% to $20.0 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $20.0 million in Q2 2026, $17.4 million in Q1 2026, and $19.1 million in Q4 2025.